Samaritan Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 5 PAGES: 72

More Info
									     Samaritan Pharmaceuticals, Inc. – Product Pipeline
                    Review – H2 2011
                                                                                          Reference Code: GMDHC01767CDB

                                                                                                 Publication Date: NOV 2011




Samaritan Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011                         GMDHC01767CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Samaritan Pharmaceuticals, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 5
Samaritan Pharmaceuticals, Inc. Snapshot .............................................................................................................................................................. 6
      Samaritan Pharmaceuticals, Inc. Overview ........................................................................................................................................................ 6
      Key Information .................................................................................................................................................................................................. 6
      Key Facts ........................................................................................................................................................................................................... 6
Samaritan Pharmaceuticals, Inc. – Research and Development Overview ............................................................................................................... 7
      Key Therapeutic Areas ....................................................................................................................................................................................... 7
Samaritan Pharmaceuticals, Inc. – Pipeline Review ................................................................................................................................................. 9
      Pipeline Products by Stage of Development ....................................................................................................................................................... 9
      Pipeline Products – Monotherapy .....................................................................................................................................................................10
Samaritan Pharmaceuticals, Inc. – Pipeline Products Glance ..................................................................................................................................11
      Samaritan Pharmaceuticals, Inc. – Late Stage Pipeline.....................................................................................................................................11
            Phase III Products/Combination Treatment Modalities ................................................................................................................................11
      Samaritan Pharmaceuticals, Inc. Clinical Stage Pipeline Products ....................................................................................................................12
            Phase II Products/Combination Treatment Modalities .................................................................................................................................12
            Phase I Products/Combination Treatment Modalities ..................................................................................................................................13
      Samaritan Pharmaceuticals, Inc.–Early Stage Pipeline Products.......................................................................................................................14
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................14
Samaritan Pharmaceuticals, Inc. – Drug Profiles .....................................................................................................................................................15
      SP-01A .............................................................................................................................................................................................................15
            Product Description ....................................................................................................................................................................................15
            Mechanism of Action...................................................................................................................................................................................15
            R&D Progress .............................................................................................................................................................................................15
      SP-08................................................................................................................................................................................................................17
            Product Description ....................................................................................................................................................................................17
            Mechanism of Action...................................................................................................................................................................................17
            R&D Progress .............................................................................................................................................................................................17
      SP-10................................................................................................................................................................................................................18
            Product Description ....................................................................................................................................................................................18
            Mechanism of Action...................................................................................................................................................................................18
            R&D Progress .............................................................................................................................................................................................18
      SP-30................................................................................................................................................................................................................19
            Product Description ....................................................................................................................................................................................19
            Mechanism of Action...................................................................................................................................................................................19
            R&D Progress .............................................................................................................................................................................................19
      SP-6300 ............................................................................................................................................................................................................20
            Product Description ....................................................................................................................................................................................20
            Mechanism of Action...................................................................................................................................................................................20
            R&D Progress .............................................................................................................................................................................................20
      SP-6310 ............................................................................................................................................................................................................21
            Product Description ....................................................................................................................................................................................21
            Mechanism of Action...................................................................................................................................................................................21
            R&D Progress .............................................................................................................................................................................................21
      SP-sc4 ..............................................................................................................................................................................................................22




Samaritan Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011                                                                                         GMDHC01767CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Samaritan Pharmaceuticals, Inc. – Product Pipeline Review



           Product Description ....................................................................................................................................................................................22
           Mechanism of Action...................................................................................................................................................................................22
           R&D Progress .............................................................................................................................................................................................22
     SP-sc7 ..............................................................................................................................................................................................................23
           Product Description ....................................................................................................................................................................................23
           Mechanism of Action...................................................................................................................................................................................23
           R&D Progress .............................................................................................................................................................................................23
Samaritan Pharmaceuticals, Inc. – Pipeline Analysis ...............................................................................................................................................24
     Samaritan Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class ......................................................................................................24
     Samaritan Pharmaceuticals, Inc. - Pipeline Products By Target ........................................................................................................................25
     Samaritan Pharmaceuticals, Inc. – Pipeline Products by Route of Administration..............................................................................................26
     Samaritan Pharmaceuticals, Inc. – Pipeline Products by Molecule Type ...........................................................................................................27
Samaritan Pharmaceuticals, Inc. – Locations And Subsidiaries ...............................................................................................................................28
     Head Office .......................................................................................................................................................................................................28
     Other Locations & Subsidiaries .........................................................................................................................................................................28
Recent Developments .............................................................................................................................................................................................29
           Nov 30, 2007: Samaritan Presents Favorable Caprospinol Data At Alzheimer's Drug Development Summit ..............................................29
           Jan 25, 2007: Samaritan Pharma's SP-10 Hip On Hep C............................................................................................................................29
           Feb 22, 2007: Samaritan Pharma Files Patent To Protect SP-04 As Bioterrorism Nerve Gas Antidote .......................................................29
           Nov 21, 2006: United States Patent Application Published For Samaritan's Novel Alzheimer's Drug SP-04 ................................................30
           Sep 18, 2007: FDA Accepts Samaritan's Cushing's SP-6300 IND and Clears Phase II Study .....................................................................30
           Nov 13, 2007: New Drug SP-233 (Caprospinol) Of Samaritan Pharmaceuticals May Restore Memory With Alzheimer's Disease ..............31
           Jul 10, 2008: Samaritan's HIV Drug Granted IND From FDA ......................................................................................................................31
           Apr 10, 2007: Samaritan Announces The Granting Of European Patent For New Type Of Cardiovascular Plaque Clearing Drug SP-1000 31
           Dec 07, 2006: Samaritan's Alzheimer's Drug SP-233 (Caprospinol) Receives IND Number From FDA.......................................................32
           Feb 06, 2007: Samaritan Pharma Aims At SP-6300 as New Innovative Treatment for Cushing's Syndrome...............................................32
Financial Deals Landscape......................................................................................................................................................................................33
     Samaritan Pharmaceuticals, Inc., Deals Summary ............................................................................................................................................33
Samaritan Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details .......................................................................................................35
     Asset Transactions............................................................................................................................................................................................35
           Samaritan Pharmaceuticals Reacquires Canadian Rights To Anticort .........................................................................................................35
     Partnerships ......................................................................................................................................................................................................37
           EUSA Pharma Signs Distribution Agreement With Samaritan Pharmaceuticals ..........................................................................................37
           Samaritan Pharmaceuticals Signs An Agreement With Shire Human Genetic.............................................................................................38
           Samaritan Pharmaceuticals Enters Into Collaboration With Pharmaplaz .....................................................................................................39
           Samaritan Pharmaceuticals Enters Into Marketing Agreement With Shire.....................
								
To top